MorphoSys AG (FSE: MOR; Prime Standard Segment) announced today that the 3-for-1 stock split of the MorphoSys share, which was resolved by the Company's shareholders at the Annual Shareholder Meeting on May 14, 2008, will be implemented on December 23, 2008. The first day of trading on a split-adjusted basis will be December 23, 2008.
By implementing the stock split, all existing non-par value shares of MorphoSys AG with a current par-equivalent value of EUR 3.00 will be divided into three shares each with a par-equivalent value of EUR 1.00, with a corresponding adjustment to the most recently quoted price. The resulting changes to the Articles of Association have been entered into the commercial register. Following the split, each shareholder will automatically hold three shares for each share previously held.
'We expect this stock split to increase accessibility of the stock to various investors, which should ultimately improve the liquidity of the MorphoSys share,' explained Dave Lemus, Chief Financial Officer of MorphoSys AG.
For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Manager Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-454, brkulj@morphosys.com
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further information please visit http://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.